FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994193684> ?p ?o ?g. }

• W1994193684 endingPage "203" @default.
• W1994193684 startingPage "201" @default.
• W1994193684 abstract "Alzheimer’s disease (AD) affects more than 25% of individuals over 80 years of age and its prevalence is expected to rise with the increase of life expectancy. Existing drugs only provide symptomatic benefits but there are no currently available diseasemodifying therapies. However, evidence from preclinical studies indicates that several drugs approved for other indications could have beneficial effects on Alzheimer’s pathology, and some of them are currently being evaluated in clinical trials [1]. In the last decades an increase in the incidence of both type 2 diabetes (T2D) and neurodegenerative disorders has been observed, posing a significant health and social challenge due to increased morbidity and mortality. T2D increases the risk of AD and there is an increased incidence of T2D in AD patients [2], probably due to common pathophysiological mechanisms shared between these diseases, and one that can be identified is insulin desensitization. Indeed, in AD brain, insulin signaling is desensitized, showing a molecular profile similar to that found in peripheral tissues of diabetic subjects [3]. Glucagon-like peptide-1 (GLP-1) is an incretin hormone with several effects on glycemic homeostasis, stimulating insulin and decreasing glucagon secretion. Currently, the GLP-1 receptor agonists exendin-4, liraglutide and lixisenatide are approved for treatment of T2D [4]. Besides its metabolic effects, GLP-1 has also been shown to act as a growth factor in the brain, inducing neurite growth and protecting against oxidative injury; GLP-1 receptor knock-out mice present with impaired hippocampal long-term potentiation of synaptic transmission [5]. The GLP-1 receptor is found in neurons throughout the nervous system, is maintained during aging and disease, and GLP-1 and its analogs effectively cross the blood–brain barrier. In the context of AD-related brain amyloid pathology, the preclinical results of GLP-1 analogs have shown promising potential. Exendin-4 has been shown to reduce endogenous levels of β-amyloid in the mouse brain [6]. Liraglutide has also been shown to protect synapses from the detrimental effects of amyloid [7,8] and it was able to significantly reduce the β-amyloid plaque load and the total amount of β-amyloid in the brain of a transgenic mouse model of AD. Importantly, in a late-stage animal model of AD, liraglutide demonstrated restorative effects in both brain structure and function, reducing both β-amyloid plaques and soluble amyloid oligomers [9], suggesting that liraglutide could potentially influence the amyloid production. Moreover, GLP-1 analogs have been demonstrated to promote cell proliferation in the rat hippocampus and increase the number of neuronal progenitor cells in mouse models of diabetes. GLP-1R activators induce the differentiation of neuronal stem cell and stimulate neurite outgrowth in a manner similar to nerve “…preclinical evidence strongly supports the hypothesis that GLP-1 analogs can represent promising candidates for Alzheimer’s disease treatment.”" @default.
• W1994193684 created "2016-06-24" @default.
• W1994193684 creator A5036174826 @default.
• W1994193684 creator A5051736407 @default.
• W1994193684 date "2014-03-01" @default.
• W1994193684 modified "2023-10-18" @default.
• W1994193684 title "The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimer’s disease" @default.
• W1994193684 cites W1515929023 @default.
• W1994193684 cites W1546941007 @default.
• W1994193684 cites W1967256054 @default.
• W1994193684 cites W1979509360 @default.
• W1994193684 cites W1985305554 @default.
• W1994193684 cites W1994735836 @default.
• W1994193684 cites W2006568691 @default.
• W1994193684 cites W2030270894 @default.
• W1994193684 cites W2060170946 @default.
• W1994193684 cites W2084899590 @default.
• W1994193684 cites W2093534363 @default.
• W1994193684 cites W2102071852 @default.
• W1994193684 cites W2123319002 @default.
• W1994193684 cites W2152835319 @default.
• W1994193684 doi "https://doi.org/10.4155/cli.14.12" @default.
• W1994193684 hasPublicationYear "2014" @default.
• W1994193684 type Work @default.
• W1994193684 sameAs 1994193684 @default.
• W1994193684 citedByCount "0" @default.
• W1994193684 crossrefType "journal-article" @default.
• W1994193684 hasAuthorship W1994193684A5036174826 @default.
• W1994193684 hasAuthorship W1994193684A5051736407 @default.
• W1994193684 hasConcept C126322002 @default.
• W1994193684 hasConcept C134018914 @default.
• W1994193684 hasConcept C169760540 @default.
• W1994193684 hasConcept C185592680 @default.
• W1994193684 hasConcept C2776398474 @default.
• W1994193684 hasConcept C2777180221 @default.
• W1994193684 hasConcept C2778563252 @default.
• W1994193684 hasConcept C2779134260 @default.
• W1994193684 hasConcept C2779281246 @default.
• W1994193684 hasConcept C502032728 @default.
• W1994193684 hasConcept C55493867 @default.
• W1994193684 hasConcept C555293320 @default.
• W1994193684 hasConcept C71315377 @default.
• W1994193684 hasConcept C71924100 @default.
• W1994193684 hasConcept C86803240 @default.
• W1994193684 hasConcept C98274493 @default.
• W1994193684 hasConceptScore W1994193684C126322002 @default.
• W1994193684 hasConceptScore W1994193684C134018914 @default.
• W1994193684 hasConceptScore W1994193684C169760540 @default.
• W1994193684 hasConceptScore W1994193684C185592680 @default.
• W1994193684 hasConceptScore W1994193684C2776398474 @default.
• W1994193684 hasConceptScore W1994193684C2777180221 @default.
• W1994193684 hasConceptScore W1994193684C2778563252 @default.
• W1994193684 hasConceptScore W1994193684C2779134260 @default.
• W1994193684 hasConceptScore W1994193684C2779281246 @default.
• W1994193684 hasConceptScore W1994193684C502032728 @default.
• W1994193684 hasConceptScore W1994193684C55493867 @default.
• W1994193684 hasConceptScore W1994193684C555293320 @default.
• W1994193684 hasConceptScore W1994193684C71315377 @default.
• W1994193684 hasConceptScore W1994193684C71924100 @default.
• W1994193684 hasConceptScore W1994193684C86803240 @default.
• W1994193684 hasConceptScore W1994193684C98274493 @default.
• W1994193684 hasIssue "3" @default.
• W1994193684 hasLocation W19941936841 @default.
• W1994193684 hasOpenAccess W1994193684 @default.
• W1994193684 hasPrimaryLocation W19941936841 @default.
• W1994193684 hasRelatedWork W1992290574 @default.
• W1994193684 hasRelatedWork W2012525570 @default.
• W1994193684 hasRelatedWork W2048352852 @default.
• W1994193684 hasRelatedWork W2048998821 @default.
• W1994193684 hasRelatedWork W2066291030 @default.
• W1994193684 hasRelatedWork W2108282017 @default.
• W1994193684 hasRelatedWork W2153965615 @default.
• W1994193684 hasRelatedWork W2339230445 @default.
• W1994193684 hasRelatedWork W2743174471 @default.
• W1994193684 hasRelatedWork W2885933730 @default.
• W1994193684 hasVolume "4" @default.
• W1994193684 isParatext "false" @default.
• W1994193684 isRetracted "false" @default.
• W1994193684 magId "1994193684" @default.
• W1994193684 workType "article" @default.